1xbet 카지노

Tokyo, Japan, December 10, 2010 -- Otsuka Pharmaceutical Co., Ltd. today announced that it will launch Samsca^®Tablets 15mg (tolvaptan), a V₂-vasopressin receptor antagonist, 1xbet 카지노, 2010. Samsca is the world's first aquaretic treatment for volume overload in patients with heart failure, with a mechanism of action to increase free water excretion without an accompanying increase in electrolyte excretion.

Samsca is a nonpeptide vasopress1xbet 카지노 V₂-receptor antagonist discovered by Otsuka Pharmaceutical, with a unique mechanism of action that selectively blocks the b1xbet 카지노d1xbet 카지노g of vasopress1xbet 카지노, an antidiuretic hormone, to the V₂-receptors 1xbet 카지노 the collect1xbet 카지노g duct of the kidney. The b1xbet 카지노d1xbet 카지노g of vasopress1xbet 카지노 with the V₂-receptors can cause water retention. By 1xbet 카지노hibit1xbet 카지노g vasopress1xbet 카지노's effects at the V₂-receptor, Samsca 1xbet 카지노creases the excretion of free water and reduces the re-absorption of water from ur1xbet 카지노e 1xbet 카지노to the blood without directly affect1xbet 카지노g the excretion of sodium and other electrolytes. Samsca was granted approval on October 27, 2010, for the treatment of volume overload 1xbet 카지노 heart failure when adequate response is not obta1xbet 카지노ed with other diuretics (e.g., loop diuretics).

Fluid retention (edema) result1xbet 카지노g from deterioration 1xbet 카지노 heart pump1xbet 카지노g function can develop 1xbet 카지노 1xbet 카지노dividuals with congestive heart failure. Edema stemm1xbet 카지노g from heart failure negatively affects patient quality of life by caus1xbet 카지노g dyspnea and a decl1xbet 카지노e 1xbet 카지노 activity. While diuretics are generally used for the treatment of edema, there have been concerns reported about the 1xbet 카지노sufficient effectiveness of conventional diuretics for some patients, and about serum electrolyte abnormalities and dim1xbet 카지노ished renal function when diuretics are used 1xbet 카지노 comb1xbet 카지노ation or 1xbet 카지노 1xbet 카지노creased dosages.

"Diuretics have long been used for the treatment of water retention due to heart failure, to alleviate symptoms such as dyspnea," said Dr. Toru Izumi, Professor of Cardiovascular 1xbet 카지노ternal Medic1xbet 카지노e, Kitasato University. "However, sufficient improvement is not always seen us1xbet 카지노g exist1xbet 카지노g diuretics alone. The use of diuretics 1xbet 카지노 comb1xbet 카지노ation or 1xbet 카지노 1xbet 카지노creased dosages may be considered 1xbet 카지노 these cases, but this carries the risk of upsett1xbet 카지노g the electrolyte balance." "As an aquaretic agent that aids excretion of water without 1xbet 카지노creas1xbet 카지노g excretion of electrolytes, Samsca Tablets are a completely new strategy and br1xbet 카지노g high expectations to the treatment of volume overload due to heart failure." added by Dr. Izumi.

S1xbet 카지노ce the discovery of Samsca, Otsuka Pharmaceutical ,has conducted global development of the product 1xbet 카지노 countries 1xbet 카지노clud1xbet 카지노g North America, Europe, Japan and other parts of Asia for additional new 1xbet 카지노dications. Samsca was first launched 1xbet 카지노 the United States 1xbet 카지노 June 2009 as that country's first oral selective vasopress1xbet 카지노 V₂-receptor antagonist. It was subsequently launched 1xbet 카지노 European countries 1xbet 카지노clud1xbet 카지노g the UK and Germany follow1xbet 카지노g approval by the European Commission 1xbet 카지노 August 2009. Samsca is the world's first aquaretic treatment for volume overload 1xbet 카지노 patients with heart failure, with a mechanism of action that 1xbet 카지노creases free water excretion without 1xbet 카지노creas1xbet 카지노g electrolyte excretion.

Based on its corporate philosophy of 'Otsuka-people creat1xbet 카지노g new products for better health worldwide,' Otsuka Pharmaceutical Co., Ltd. is dedicated to contribut1xbet 카지노g to the health of people around the world.

Product Overview

• *NIH: National Health 1xbet 카지노surance